BLA 125561 · Alexion Pharm
Kanuma
Sebelipase Alfa · Injection
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Dec 8, 2015
Approved uses
2
Original approval plus efficacy supplements
Registered trials
7
2 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate KANUMA in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue KANUMA and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) ]. WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS...
What it is approved for
From the label in effect Oct 23, 2026.
KANUMA ® is indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency. KANUMA ® is a hydrolytic lysosomal cholesteryl ester and triacylglycerol-specific enzyme indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency. ( 1 )
Mechanism: LAL deficiency is an autosomal recessive lysosomal storage disorder characterized by a genetic defect resulting in a marked decrease or loss in activity of the lysosomal acid lipase (LAL) enzyme. The primary site of action of the LAL enzyme is the lysosome, where the enzyme normally causes the breakdown of lipid particles, including LDL-c and triglycerides. Deficient LAL enzyme activity results in progressive complications due to the lysosomal accumulation of cholesteryl esters and triglycerides in multiple organs, including the liver, spleen, intestine, and the walls of blood vessels. The...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 19, 2021 Supplement 13 · Efficacy OrphanLabelLetter
- Dec 8, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
- KANUMA · SEBELIPASE ALFA 20MG/10ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sebelipase Alfa" as an intervention, any sponsor and status, largest first.
- Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase DeficiencyPivotal-lookingCompleted
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT01757184 · 66 participants · Start Jan 22, 2013 · Primary completion May 30, 2014
Drug: Sebelipase Alfa; Placebo · For: Lysosomal Acid Lipase Deficiency
Sites: Tucson, Arizona; Palo Alto, California; San Francisco, California · 40 sites in all
- Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase DeficiencyCompleted
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT02112994 · 31 participants · Start Jun 24, 2014 · Primary completion Dec 28, 2017
Drug: Sebelipase Alfa · For: Lysosomal Acid Lipase Deficiency
Sites: Chicago, Illinois; Shreveport, Louisiana; Cincinnati, Ohio · 19 sites in all
University of California, San FranciscoAcademic, hospital or other
NCT04532047 · 10 participants (planned) · Start Jul 1, 2021 · Primary completion Jul 31, 2031
Drug: Aldurazyme (laronidase) · For: MPS I; MPS II; MPS IVA and 6 more
Sites: San Francisco, California
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT02193867 · 10 participants · Start Jun 6, 2014 · Primary completion Oct 30, 2018
Drug: Sebelipase Alfa · For: Lysosomal Acid Lipase Deficiency
Sites: Phoenix, Arizona; Kuopio, Finland; Naples, Italy · 5 sites in all
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT01307098 · 9 participants · Start Apr 25, 2011 · Primary completion Jan 6, 2012
Drug: Sebelipase alfa 0.35 mg/kg; Sebelipase alfa 1 mg/kg and 1 more · For: Cholesterol Ester Storage Disease(CESD); Lysosomal Acid Lipase Deficiency; LAL-Deficiency
Sites: Stanford, California; New York, New York; Pittsburgh, Pennsylvania · 7 sites in all
- Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase DeficiencyPivotal-lookingCompleted
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT01371825 · 9 participants · Start May 4, 2011 · Primary completion Jan 3, 2018
Drug: Sebelipase alfa (SBC-102) · For: Lysosomal Acid Lipase Deficiency; Wolman Disease
Sites: Irvine, California; Cairo, Egypt; Grenoble, France · 7 sites in all
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT01488097 · 8 participants · Start Dec 12, 2011 · Primary completion Jun 21, 2017
Drug: sebelipase alfa · For: Cholesterol Ester Storage Disease (CESD); Lysosomal Acid Lipase Deficiency; LAL-Deficiency
Sites: Eureka, California; Sacramento, California; San Francisco, California · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-Term Sebelipase Alfa Treatment in Children and Adults With Lysosomal Acid Lipase Deficiency.
Burton BK, Sanchez AC, Kostyleva M, et al. · J Pediatr Gastroenterol Nutr 2022 · Clinical Trial, Research Support, Non-U.S. Gov't
- Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency.
Valayannopoulos V, Malinova V, Honzík T, et al. · J Hepatol 2014 · Clinical Trial, Multicenter Study
- Sebelipase alfa for lysosomal acid lipase deficiency: 5-year treatment experience from a phase 2 open-label extension study.
Malinová V, Balwani M, Sharma R, et al. · Liver Int 2020 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency.
Wilson DP, Friedman M, Marulkar S, et al. · J Clin Lipidol 2018 · Clinical Trial, Research Support, Non-U.S. Gov't
- Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study.
Jones SA, Rojas-Caro S, Quinn AG, et al. · Orphanet J Rare Dis 2017 · Clinical Trial, Multicenter Study
- A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency.
Burton BK, Balwani M, Feillet F, et al. · N Engl J Med 2015 · Clinical Trial, Phase III, Multicenter Study
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.